4th place at Science4Life | Polyneuron Pharmaceuticals

Skip to navigation
Skip to main content

July 15, 2015 Awards
4th place at Science4Life

Polyneuron is in the top5 start-up teams at the Science4Life start-up competition in Germany.

In other news

April 23, 2021 General
Polyneuron and University of Basel awarded grant of CHF 1.2 M to advance novel treatments to support ABO-Incompatible transplants

Polyneuron is proud to announce that – together with the… [read on]
October 7, 2020 Uncategorized
Polyneuron appoints Aled Williams as chief business officer

We are extremely pleased to welcome Aled Williams to Polyneuron… [read on]
September 16, 2020 General
Polyneuron extends Series A to CHF 36.5 million

Polyneuron announces a CHF 14 million extension of the Series… [read on]
June 5, 2020 General
Polyneuron's PN-1007 Receives U.S. FDA Orphan Drug Designation in Anti-MAG Neuropathy

Polyneuron is proud to announce that the U.S. Food and… [read on]
April 27, 2020 General
Polyneuron receives approval to begin clinical study with PN-1007 in anti-MAG neuropathy

We are very proud to have received our… [read on]
April 7, 2020 General
Polyneuron announces appointment of chief medical officer

We are extremely pleased to welcome Dr Debra Barker to… [read on]
September 5, 2019 General
Polyneuron annouces appointment of new Chairman

Polyneuron announces the appointment of Ben Machielse as Chairman of… [read on]
March 28, 2019 Financing
Polyneuron raises CHF 22.5 million in a major Series A financing

Polyneuron raises CHF 22.5 million in an oversubscribed… [read on]